Articles

Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …

A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners …

A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication. Stories like these are hard to ignore, and they have helped fuel growing enthusiasm around drugs like Ozempic, Wegovy, and Mounjaro. Yet as prescriptions continue to expand beyond high-risk diabetes …

The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are …

For many patients with obesity-related osteoarthritis, daily movement can feel like walking with a heavy backpack that never comes off. Joint pain limits exercise, reduced activity leads to more weight gain, and the cycle continues. However, new research is raising an important question: could GLP-1 therapies help break that cycle? …

What if a medication designed to lower blood sugar could also help protect the brain? That question is driving growing interest among researchers studying the connection between GLP-1 drugs and Parkinson’s disease. Scientists are now exploring whether therapies originally developed for type 2 diabetes and obesity may influence inflammation, neuronal …

Managing post-meal glucose levels plays a critical role in diabetes care, yet it is often overlooked in favor of A1C and time in range. However, what happens after meals can significantly affect long-term outcomes. Think of it like traffic flow: even if the highway looks clear overall, sudden congestion at …

What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it? Early GLP-1 therapy is gaining attention as clinicians rethink traditional treatment timelines. Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and …

Rapid glycemic improvement with GLP-1 therapy is one of the most powerful benefits of modern diabetes care, but it can also create new clinical challenges. When glucose levels drop quickly, patients may face an increased risk of hypoglycemia if other medications are not adjusted in time. So, how do clinicians …

As virtual care becomes more common, many clinicians now initiate GLP-1 receptor agonist therapy remotely. But how do you ensure patient safety without in-person visits? Effective remote monitoring of GLP-1 therapy plays a critical role in closing care gaps while maintaining treatment effectiveness. Much like managing insulin therapy from a …